Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib and Rucaparib in advanced breast, ovarian, or prostate cancer
NCT03840200Phase 1Completed
- Sponsor
- Roche
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of ipatasertib in breast cancer, ovarian cancer and prostate cancer (PCa) (5 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events up to 2 years, Percentage of Participants With Dose-Limiting Toxicities and 1 more. Started Jun 2019; status: completed.
02
Drugs
ipatasertib
03
Conditions
breast cancerovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT03840200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840200.